T2 Biosystems to Participate in the Canaccord Genuity Virtual MedTech & Diagnostics Forum

Rhea-AI Summary

T2 Biosystems (NASDAQ: TTOO), a leader in rapid detection of sepsis-causing pathogens, will participate in the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 2:30 PM ET. The presentation will be accessible via a live and recorded webcast on the company’s website.

The company is dedicated to enhancing patient care and lowering costs with innovative products like the T2Dx® Instrument and various diagnostic panels, driven by their proprietary T2 Magnetic Resonance (T2MR®) technology.

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming Canaccord Genuity Virtual MedTech & Diagnostics Forum.

Management is scheduled to present Thursday, November 19, 2020 at 2:30pm ET. Interested parties may access a live and recorded webcast of the presentation on the “Investors” section of the Company’s website at www.t2biosystems.com.

About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx^® Instrument, T2Candida^® Panel, the T2Bacteria^® Panel, the T2Resistance^® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR^®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.

Media Contact:
Gina Kent, Vault Communications
gkent@vaultcommunications.com
610-455-2763

Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406

FAQ

What is T2 Biosystems' participation in the Canaccord Genuity Virtual MedTech Forum?

T2 Biosystems will present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 2:30 PM ET.

Where can I watch T2 Biosystems' presentation?

The presentation can be accessed through a live and recorded webcast on T2 Biosystems' website.

What products does T2 Biosystems offer?

T2 Biosystems offers products like the T2Dx® Instrument, T2Candida® Panel, T2Bacteria® Panel, T2Resistance® Panel, and the T2SARS-CoV-2™ Panel.

How does T2 Biosystems improve patient care?

T2 Biosystems improves patient care by providing rapid detection of sepsis-causing pathogens, enabling faster and more effective treatment.

What technology powers T2 Biosystems' products?

T2 Biosystems' products are powered by their proprietary T2 Magnetic Resonance (T2MR®) technology.